About Imanova Ltd
Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK's Medical Research Council and three world-class London universities: Imperial College London, King’s College London and University College London. Imanova is a company with a depth of understanding in drug development and extensive experience using imaging to facilitate the development pipeline. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivalled capabilities to facilitate drug development.
Imanova has the state-of-the-art technology and skills to attach a radioisotope to a drug candidate which researchers can use to capture images and generate quantitative data detailing the distribution of their drug using a functional imaging technique called positron emission tomography (PET) imaging.
Using PET imaging, researchers can visualise the absorption, distribution, metabolism and excretion properties. Additionally, one of the key benefits of PET imaging is the ability to visualise candidate target-engagement in vivo. This allows researchers and companies to accurately predict the effectiveness of a drug within human earlier within the drug development process, ensuring the resources are used efficiently and effectively.
In addition to the PET imaging we also specialise in the utilisation of state of the art magnetic resonance imaging (MRI) to provide advanced structural and functional information. We have the knowledge, experience and the expertise to provide end-to-end support to clients and collaborators.
Former Head of Communities, Springer Nature
Editor, BioPharma Dealmakers , Nature Publishing Group
CEO & Co-Founder, Zapnito
Managing Director, Thoroughly Good Consulting
Sales Account Executive, Springer Nature
Topics contributed to: